GERM ETFMG Treatments, Testing and Advancements ETF
Quote as of Sep 05, 2024 19:53 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 19.21 | Day Range | 19.16 – 19.28 |
| 52-Week Range | 16.32 – 20.20 | Volume | 4.83K |
| Avg Volume | 1.20K | AUM | $9.7M (Aug 27, 2026) |
| Expense Ratio | 0.68% | Yield (TTM) | — |
| NAV | 19.34 | Premium/Discount | -0.94% indicative |
| Inception | Jun 18, 2020 | Holdings | 57 |
| Issuer | Amplify | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 032108581 | ISIN | US0321085815 |
| Management | Passive / index-tracking (per issuer description) | ||
About this ETF
The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +3.01% | -3.72% | +5.62% | -2.04% | -0.16% | -24.61% | — | — | -6.25% |
| Total return | +3.01% | -3.28% | +6.44% | -1.29% | +1.11% | -23.94% | — | — | -5.42% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Sep 05, 2024. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.68% | Annual cost of a $10,000 investment | $68.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 11, 2024 — portfolio reporting date from the data provider; holdings are not live positions. 57 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Alnylam Pharmaceuticals Inc | ALNY | 11.39% | 3.96K | $1.1M |
| 2 | Labcorp Holdings Inc | LH | 7.20% | 2.98K | $674.4K |
| 3 | Quest Diagnostics Inc | DGX | 6.61% | 4.14K | $618.4K |
| 4 | BioNTech SE | BNTX | 5.01% | 5.80K | $468.9K |
| 5 | Bio-Rad Laboratories Inc | BIO | 4.74% | 1.36K | $443.4K |
| 6 | Vaxcyte Inc | PCVX | 4.52% | 5.43K | $423.1K |
| 7 | QuidelOrtho Corp | QDEL | 4.11% | 9.25K | $385.0K |
| 8 | BioCryst Pharmaceuticals Inc | BCRX | 3.70% | 45.43K | $346.6K |
| 9 | Immunocore Holdings PLC | IMCR | 3.67% | 9.23K | $343.2K |
| 10 | Zai Lab Ltd | ZLAB | 3.60% | 20.73K | $337.1K |
| 11 | Moderna Inc | MRNA | 3.46% | 3.82K | $324.3K |
| 12 | Dynavax Technologies Corp | DVAX | 3.42% | 28.81K | $319.8K |
| 13 | ImmunityBio Inc | IBRX | 3.14% | 64.67K | $293.6K |
| 14 | Vir Biotechnology Inc | VIR | 2.79% | 29.95K | $260.8K |
| 15 | Novavax Inc | NVAX | 2.50% | 20.14K | $233.6K |
| 16 | OPKO Health Inc | OPK | 2.46% | 153.42K | $230.1K |
| 17 | CureVac NV | CVAC | 1.73% | 49.37K | $161.9K |
| 18 | Fulgent Genetics Inc | FLGT | 1.68% | 6.59K | $157.6K |
| 19 | Arbutus Biopharma Corp | ABUS | 1.62% | 41.54K | $151.6K |
| 20 | Adaptive Biotechnologies Corp | ADPT | 1.55% | 32.44K | $145.0K |
| 21 | SIGA Technologies Inc | SIGA | 1.45% | 15.65K | $136.0K |
| 22 | Arcturus Therapeutics Holdings Inc | ARCT | 1.14% | 5.93K | $107.2K |
| 23 | Gilead Sciences Inc | GILD | 1.01% | 1.28K | $94.7K |
| 24 | Regeneron Pharmaceuticals Inc | REGN | 0.99% | 82 | $92.8K |
| 25 | AbbVie Inc | ABBV | 0.98% | 484 | $91.9K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 27, 2024 | Last payment | $0.0880 (Jun 28, 2024) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 27, 2024 | Jun 27, 2024 | Jun 28, 2024 | $0.0880 |
| Mar 26, 2024 | Mar 27, 2024 | Mar 28, 2024 | $0.0558 |
| Dec 27, 2023 | Dec 28, 2023 | Dec 29, 2023 | $0.0522 |
| Sep 20, 2023 | Sep 21, 2023 | Sep 22, 2023 | $0.0400 |
| Jun 21, 2023 | Jun 22, 2023 | Jun 23, 2023 | $0.0600 |
| Mar 22, 2023 | Mar 23, 2023 | Mar 24, 2023 | $0.0900 |
| Dec 28, 2022 | Dec 29, 2022 | Dec 30, 2022 | $0.0290 |
| Sep 21, 2022 | Sep 22, 2022 | Sep 23, 2022 | $0.0600 |
| Dec 28, 2021 | Dec 29, 2021 | Dec 30, 2021 | $0.0010 |
| Sep 21, 2021 | Sep 22, 2021 | Sep 23, 2021 | $0.0400 |
| Dec 14, 2020 | Dec 15, 2020 | Dec 16, 2020 | $0.2850 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | — / — | Sharpe 1Y / 3Y | — / — |
| Max drawdown 1Y / 3Y | — / — | Sortino 1Y | — |
| Beta vs S&P 500 (3Y) | 0.758 | Correlation vs S&P 500 (1Y) | — |
| Downside deviation 1Y | — | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 4.83K | Average volume | 1.20K |
| AUM | $9.7M | Premium/Discount | -0.94% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for GERM
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.